Sai Parenterals Subsidiary Secures 7.5 Year Exclusive OTC Medicine Supply Agreement with Australia Network
Sai Parenterals Limited's subsidiary, Noumed Pharmaceuticals Pvt Limited, has secured a significant international contract involving the supply of OTC medicines. The company has entered into an exclusive supply agreement with Australia's leading pharmacy network, valued at Australian Dollars (AUD) 202 Million, which is equivalent to INR 1300 crores.The agreement establishes Noumed Pharmaceuticals as the exclusive supplier of OTC medicines to the international entity for a term spanning 7.5 years. The contract includes an option for further extension by an additional three years upon mutual consent.
This strategic partnership with the Australian pharmacy network highlights the expanding global reach of Sai Parenterals’ operations in the pharmaceutical sector. The transaction is classified as a wholly international undertaking, and the company confirmed that neither the promoter group nor any related parties hold an interest in the entity awarding the contract. Furthermore, the deal will not fall under related party transactions.
Key details regarding the supply agreement are provided below:
| Contract Detail | Specification |
|---|---|
| Partner Entity | Australia's Leading Pharmacy Network |
| Nature of Agreement | Exclusive OTC medicine supply agreement |
| Contract Term | 7.5 years with a three-year extension option |
| Transaction Value | AUD 202 Million (Equivalent to INR 1300 crores) |
The agreement, effective from July 01, 2026, reinforces the company's dedication to international market penetration in the pharmaceutical domain.
SAIPARENT Stock Price Movement
Sai Parenterals Limited shares gained today, climbing 4.93% and settling at ₹612.1 in post-market trading. The stock saw a volume of 790,579 shares as it managed to touch its annual high of ₹625 during the trading session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.